glp-1 companion app companies AI accelerates digital health development with Phlo's GLP1 app | Marc Sluijs posted on the topic GLP-1 Companion

Is it difficult to take the meds/what if I dont know how to do the injections?

A general caveat when analyzing the tissue distribution of the GLP-1R protein is the lack of sufficiently selective and commercially available antibodies [391]

MarketScan data shows that only 66% of continuously enrolled new GLP-1 patients were persistent on Obesity medications for at least 40 weeks (10 months) in 2022 2024, compared to 77% of patients taking Diabetes products

That could tip the scale of any judgment on their ability to enhance performance

Semaglutide has randomized trial evidence in nonalcoholic steatohepatitis demonstrating improvement in key disease activity outcomes. Tirzepatide also has randomized trial evidence in metabolic dysfunctionassociated steatohepatitis (MASH) with liver fibrosis, supporting improvements in steatohepatitis-related endpoints. Clinical takeaway: GLP-1 and GLP-1/GIP therapies can reduce liver fat and liver injury activity in metabolic liver disease settings., 3) They Improve Cardiometabolic Risk Factors That Overlap With Vascular Inflammation Vascular inflammation is an umbrella term